A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes

Clinical Infectious Diseases

Volumn 40, Issue 2, 2005, Pages 265-272

  McEllistrem, M Catherine ^a   Carman, Robert J ^b   Gerding, Dale N ^c   Genheimer, C W ^b   Zheng, L ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Tech Lab   (United States)

^c HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL TOXIN;

ABDOMINAL PAIN; ARTICLE; ASCITES; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; CLONE; CLOSTRIDIUM DIFFICILE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; EPIDEMIC; GENETIC STRAIN; GENETIC TOXICOLOGY; HOSPITAL INFECTION; HUMAN; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL;

ADP RIBOSE TRANSFERASES; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DISEASE OUTBREAKS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 12144284570     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427113     Document Type: Article

References (25)

1. Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-9.
2. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:1027-34.
3. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235:363-72.
4. Grundfest-Broniatowski S, Quader M, Alexander F, Walsh RM, Lavery I, Milsom J. Clostridium difficile colitis in the critically ill. Dis Colon Rectum 1996; 39:619-23.
5. Muto CA, Pokrywka M, Nouri K, et al. Changing the epidemiology of Clostridium difficile colitis: new implications and risk factors for disease. Salt Lake City: Society for Healthcare Epidemiology of America, 2002.
6. Blank BK, Pokrywka M, Vergis E, et al. Implementing interventions to reduce nosocomial Clostridium difficile infection rates and adverse events. Philadelphia: Society for Healthcare Epidemiology of America, 2004.
7. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38:350-4.
8. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985; 13:97-101.
9. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-93.
10. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62:384-9.
11. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997; 41:366-70.
12. Banno Y, Kobayashi T, Kono H, Watanabe K, Ueno K, Nozawa Y. Biochemical characterization and biologic actions of two toxins (D-1 and D-2) from Clostridium difficile. Rev Infect Dis 1984; 6(Suppl 1):S11-20.
13. Taylor NS, Thorne GM, Bartlett JG. Comparison of two toxins produced by Clostridium difficile. Infect Immun 1981; 34:1036-43.
14. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004; 42:1933-9.
15. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186:307-12.
16. Popoff MR, Rubin EJ, Gill DM, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988; 56:2299-306.
17. Petit L, Gibert M, Popoff MR. Clostridium perfringens: toxinotype and genotype. Trends Microbiol 1999; 7:104-10.
18. Popoff MR, Boquet P. Clostridium spiroforme toxin is a binary toxin which ADP-ribosylates cellular actin. Biochem Biophys Res Commun 1988; 152:1361-8.
19. Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002; 23:653-9.
20. Moncrief JS, Zheng L, Neville LM, Lyerly DM. Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol 2000; 38:3072-5.
21. Rafferty ME, Baltch AL, Smith RP, et al. Comparison of restriction enzyme analysis, arbitrarily primed PCR, and protein profile analysis typing for epidemiologic investigation of an ongoing Clostridium difficile outbreak. J Clin Microbiol 1998; 36:2957-63.
22. Clabots CR, Johnson S, Bettin KM, et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 1993; 31:1870-5.
23. Silva J Jr. Update on pseudomembranous colitis. West J Med 1989; 151:644-8.
24. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999; 341:1645-51.
25. McDonald LC, Killgore GE, Thompson A, Johnson S, Gerding D. Emergence of an epidemic strain of Clostridium difficile in the United States, 2001-4 [abstract LB-2]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Boston: Infectious Diseases Society of America, 2004:59.